SHARPE
Reported results
- Consolidated revenue increased 10.6% to $690.9 million.
- GAAP Diluted Earnings-per-Share (EPS) was $5.45, an increase of 22.2%.
- Adjusted Diluted EPS was $6.75, an increase of 28.1%.
- VITAS segment Net Patient Revenue increased 12.2% to $457.4 million.
- VITAS segment Adjusted EBITDA, excluding Medicare Cap, was $92.5 million, an increase of 31.4%.
- Roto-Rooter segment Adjusted EBITDA was $48.2 million, a decline of 2.5%.
Guidance
- Chemed estimates that it will be at or slightly above the high-end of its full-year 2026 adjusted EPS guidance.
Price and volatility reaction
The stock moved +4.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -12.5 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 509.09 | 2026-10-27 |
| Close after release | 533.36 | 2026-10-28 |
| Realised move | +4.8% | close to close |
| 30d ATM IV change | -12.5 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.